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The  important  role  of type-specific anticapsular  antibodies  in  host  defense 
against pneumococcal  infections is well established (1).  The  early successes of 
inducing type-specific protective  antibodies  (2)  gave  rise  to  numerous studies 
dealing  with  anticapsular  antibodies  and  the  development  of pneumococcal 
capsular polysaccharide vaccines (1). It has been suggested that antibodies to the 
pneumococcal cell wall are not opsonic and fail to protect mice from infection 
(3-5).  However,  there  have  been  occasional  reports  of protective  antibody 
specific for  noncapsular  pneumococcal  antigen(s)  (6-9).  More  recently,  it  has 
been demonstrated that monoclonal antibodies and C-reactive protein directed 
against phosphocholine (PC), 1 a  cell  wall determinant of pneumococcal  C-car- 
bohydrate  (10),  can  protect  mice  from  fatal  infections  with  several  types  of 
Streptococcus  pneumoniae (1 1  - 15). 
In the present study we have used monoclonal antibody techniques in an effort 
to characterize other cell wall determinants that may elicit protective antibody. 
xid mice, which respond poorly to carbohydrates (16,  17), were injected with an 
unencapsulated pneumococcus R36A in an effort to optimize the production of 
hybridoma antiprotein antibodies. Two hybridomas were produced which make 
antibodies  that recognized  protease-sensitive  pneumococcal  antigens and  pro- 
tected mice from infection with an encapsulated strain of S. pneumoniae. 
Materials and Methods 
Mice.  CBA/N males (xid) were obtained from Dublin Laboratories, Dominion, VA. 
CFW Swiss-Webster mice were obtained from Charles River Breeding Laboratories, Inc., 
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Wilmington,  MA.  BALB/c  mice  were  obtained  from  The Jackson  Laboratory,  Bar 
Harbor, ME. 
Bacterial Strains and Growth Conditions.  S. pneumoniae strains included type 3 strains 
WU2 (11) and A66 (18), and a type 5 strain (12), which were all kept virulent by mouse 
passage, and the unencapsulated strain R36A originally derived from the type 2 strain 
D39 (18).  A66 and D39 were obtained from Dr.  M.  McCarty and R36A from Dr.  A. 
Tomasz at The Rockefeller University. Clinical isolates of types 1, 3, 6A, 8, 9V,  10,  14, 
19F, and 23F were obtained from Barry Gray, University of Alabama in Birmingham. 
Cultures were maintained and grown as previously described (11). Log phase bacteria at 
108/ml were harvested from 7 ml of broth (Todd-Hewitt supplemented with 0.5% yeast 
extract) by centrifugation (4,000 g,  10 min, 4°C) and suspended in Ringer's lactate for 
injection into mice, or 1% phosphate-buffered saline (PBS)  for use in the binding assay. 
Alternatively,  100  ml of a  10S/ml culture was maintained at 60°C  for 60 min and the 
heat-killed organisms, washed twice with  Ringer's lactate,  were resuspended at a  final 
concentration of 109 cells/ml as determined by optical density at 420 nm (optical density 
[OD] of 1 =  2 ×  10  s colony-forming units [CFU]/ml), and checked for sterility by plating 
a sample on blood agar. The killed bacteria were stored as 5-mi aliquots at -70°C. 
Preparation ofMonoclonal  Antipneuraococcal Antibodies.  Mice were given four weekly 
intravenous injections of 2  x  l0 s heat-killed R36A in  0.2  ml of Ringer's lactate.  Mice 
were killed 5 d after the last immunization. Spleen cells from immunized mice were fused 
with  the  non-Ig-producing mouse myeloma line  P3-X63-Ag.8.653  using polyethylene 
glycol 4000 (Fisher Scientific Co., Pittsburgh, PA) as described previously (19, 20). 
After 2-3 wk, culture supernatants were screened for antibody activity against PC as 
described previously (21).  To assay for antibody to R36A, polystyrene microtiter plates 
were coated with heat-killed R36A by adding 100 #1 of l0 s cells/ml in PBS to each well. 
The plate was centrifuged at 550 g for 15 min, washed three times with PBS, and flooded 
with 1% bovine serum albumin (BSA) in PBS for 4 h at 4°C to block unreacted sites. The 
remainder of the enzyme-linked immunosorbent assay (ELISA) for anti-R36A antibody 
was carried out using alkaline phosphatase (AP) anti-mouse Igs as described previously 
for the anti-PC ELISA (19, 20). 
Hybridomas that secreted antibodies reacting with R36A but not PC were chosen for 
further study and recloned by limiting dilution  on syngeneic normal mouse peritoneal 
feeder cells.  The Ig isotypes of the hybridoma antibodies were determined at this stage 
using AP-labeled goat antibodies specific for mouse #, 3' I, 72a, ~2b, ~,3, a, x, and ~ chain 
determinants as previously described (19, 20). 
After expansion of positive reclones, 10-30 million cells were injected intraperitoneally 
into either syngeneic or nude  mice previously primed with pristane (Aldrich Chemical 
Co., Milwaukee, WI.). Ascites were harvested and the amount of R36A-binding antibody 
was determined in a quantitative ELISA assay (22) using anti-PC antibodies as standards. 
Ascites were ammonium sulfate precipitated and again quantitated for anti-R36A-binding 
antibody.  The  anti-PC,  T15-positive antibody,  22.1A4,  was provided  by  Dr.  Latham 
Claflin, University of Michigan, Ann Arbor, MI (23). 
Assay  for Antipneuraococcal Surface Binding Capacity.  Hybridoma antibodies were chlor- 
amine T-labeled with a~sI (24) for use in a surface binding assay described previously (12) 
to determine their ability to bind to  10  7 CFU in 0.3  ml. In this assay, ~TCoCls chelated 
with  0.1  mM  diethylenetriamine  pentaacetic  acid  was  used  as a  volume  marker (12). 
Various strains and serotypes of viable pneumococci were used to determine their relative 
abilities to bind the l~I-labeled antibody. In some experiments the heat-killed R36A was 
treated wth 2.5 mg/ml pepsin at 37°C, pH 2.0, for 3 h or with 2 mg/ml trypsin at 37°C, 
pH  7.5,  for  1  h.  Before  use  in  the  assay,  the  pH  of the  pepsin-treated  samples was 
neutralized  with  1  N  NaOH  (25)  and  the  bacteria  were  washed  three  times  in  PBS. 
Similarly at the end of the incubation with trypsin, the effectiveness of the trypsin was 
blocked with  soybean trypsin  inhibitor  (Sigma Chemical  Co.,  St.  Louis,  MO)  and  the 
bacteria were washed three times with PBS. Control bacteria received the same treatments 
minus the pepsin or trypsin. 
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to pneumococci. In this case various unlabeled antibodies were used to inhibit the binding 
of the labeled antibody to pneumococci. 
Inhibition  Assay.  An  ELISA  procedure  was  developed  to  determine  the  ability  of 
various pneumococcal cell components to block the binding of the hybridoma antibodies 
to heat-killed  R36A  cells.  Materials tested  included  PC  (Sigma Chemical  Co.),  type  3 
capsular  polysaccharide  (from  Phillip  Baker,  NIH),  and  C-polysaccharide (from John 
Volanakis, University of Alabama in Birmingham). After coating (with heat-killed R36A) 
and blocking of microtiter plates with BSA as described above,  100 ttl of 1% BSA were 
added to all wells.  Then 50 ttl of PBS containing a potential inhibitor were added to the 
first well and diluted threefold through seven wells using 50 #1 dilution wands (Dynatech 
Laboratories, Inc., Alexandria, VA). Samples were always assayed in duplicate. The eighth 
well  in  each  row  served  as  an  uninhibited  control.  Next,  50  #1  of a  standardized 
concentration of hybridoma antibody from culture supernatants were added to all wells. 
Plates were incubated overnight at 4°C,  washed three times with  PBS,  and developed 
with AP-conjugated goat anti-mouse antibody and AP substrate as described above. The 
OD, at 405 nm, of each well relative to the OD of the positive control was plotted. 
Preparation of Bacterial Lysate.  A modification of the procedure described by Saunders 
and Guild (26) was used to lyse pneumococci. Briefly, R36A was grown to -  1 x  109 cells/ 
ml in 500 ml of medium. Cells were harvested by centrifugation, washed once with PBS, 
and  resuspended  in  1.5  ml of lysis buffer,  0.1%  sodium  deoxycholate,  0.01%  sodium 
dodecyl sulfate, and 0.15 M sodium citrate. After 5 min at 37 ° C, 2.5 ml of dilution buffer 
(0.15  M NaC1 and 0.015  M sodium citrate) was added.  The lysate was dialyzed against 
three changes of PBS at 4°C and centrifuged at 10,000 g for 10 min to remove insoluble 
material. The amount of protein in the lysate was determined by a  Bio-Rad microassay 
(Bio-Rad Laboratories, Richmond, CA). The lysate was aliquoted and stored at -20°C 
until use. 
Trypsin  Treatment of Lysate.  In some experiments, we trypsin treated the R36A lysate 
before using it  in  the  ELISA inhibition  assay. The  lysate was  divided into  two  300-td 
samples. To one sample, 50 ttl of a 2 mg/ml solution of trypsin was added while the other 
sample received 50 td  of PBS without trypsin. The mixtures were incubated for 2 h  at 
37 °C, at which time 10 ttl of soybean trypsin inhibitor (Sigma Chemical Co.) was added 
to both samples. 
Mouse Protection  Tests.  Mice were injected  intraperitoneally with various concentra- 
tions  of antibody  diluted  in  2%  fetal  calf serum  (FCS)-Ringer's  lactate  1  h  before 
intravenous challenge with 5-10 times the LD~0 of bacteria. Control mice received diluent 
alone 1 h before challenge, hnmediately after challenging, samples of the inoculum were 
diluted  and  plated  to  determine  the  CFU.  Deaths  were  recorded  at  24-h  intervals. 
Although most deaths occurred on days 2 and 3, the mice were observed for 10 d. The 
dose for each of the hybridoma antibodies that protected 50%  of infected mice (PD.~0) 
was calculated by the method of Reed and Muench (27). 
Results 
Antibody  Characterization.  Cells  from  the  fusion  of  P3-XB3-Ag.8.653  with 
anti-R36A-immune  CBA/N  spleen  cells  were  plated  into  192  wells.  Of these 
192,  170  (88.5%)  contained  growing  hybrids.  A  total  of 42  (21.9%)  hybrids 
produced antibody that bound to R36A, and  17 of these produced antibody that 
did not bind PC. Three of these latter hybrids were recloned and expanded for 
further study: Xi64 (IgM,K), Xi69 (IgM,K), and Xi126 (IgG2b,r). 
Using  the  same  procedures,  hybridomas  were  produced  from  the  fusion  of 
spleen cells from a  BALB/c mouse that had been immunized with R36A.  Of 92 
growing hybrids,  14  produced  antibody that  bound  R36A.  The  antibody pro- 
duced  by  two  of these  failed  to  bind  to  PC.  One  of these  latter  hybrids  was 
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Lack of Reactivity with Polysaccharides.  Possible reactivity of Xi126, Xi64, and 
Xi69 antibodies with pneumococcal cell wall  and capsular polysaccharides was 
assessed  by  using these  materials  to  attempt  inhibition  of the binding of the 
hybridoma antibodies to R36A.  By this assay all three antibodies failed to show 
reactivity with free PC, C-polysaccharide, or type 3 pneumococcal polysaccharide 
(Fig.  1). An IgG3 anti-PC antibody, 59.6C5 (23), was included as a control. Both 
PC and C-polysaccharide inhibited the binding of the anti-PC antibody to R36A. 
The less complete inhibition of the binding of this antibody to R36A by type 3 
polysaccharide was probably due to a low level of contaminating C-polysaccharide 
in the type 3 preparation. 
Supernatant  from a  culture of R36A  failed to  inhibit  the binding of these 
antibodies,  indicating that  the antigen they detect is neither released into the 
medium during bacterial growth, nor acquired from it. 
Antigen  Characterization.  The ability of all  four non-PC-binding antibodies 
to bind heat-killed R36A was greatly reduced or eliminated by treating the killed 
bacteria with pepsin or trypsin (Table I). The anti-PC antibody, 22.1A4, bound 
slightly better to pepsin- or trypsin-treated than to normal cells. These results 
indicate that the non-PC-binding antibodies recognized a cell surface determi- 
nant that was polypeptide associated. 
In  the  case  of antibody  Xi126,  we demonstrated that  its  target  is  actually 
protein and not simply a  carbohydrate held to  the cell surface by a  protease- 
sensitive polypeptide. We obtained this result using a crude lysate of R36A that 
could inhibit the binding of Xi 126 antibodies to R36A, as measured by ELISA. 
When the crude lysate was treated with trypsin, we observed a  10-fold reduction 
in its ability to block the binding of Xi126 to R36A (Fig. 2). The same trypsin- 
treated  lysate retained its  ability to  block  the binding  of 59.6C5  to  the  PC- 
containing cell wall carbohydrate of heat-killed R36A. 
Binding  of Antibody  to  Pneumococcal Strains.  Live  pneumococci of various 
strains and serotypes were used to determine the binding capacity of ~25I-labeled 
antibodies. As can be seen in Fig. 3, these antibodies vary in their ability to bind 
different pneumococci, indicating that they have different specificities. Antibody 
Xi69 appeared to be the most cross-reactive. The binding of each of the four 
antibodies was greatest to strain D39, which was the parental strain of R36A. As 
a control we included the IgM anti-PC hybridoma, 22.1A4 (23), which showed 
about 14% binding to all of the pneumococcal isolates (data not shown). Binding 
of all four antibodies to the rough strain R36A was between 50 and 60% (data 
not shown). 
Competitive Inhibition of Binding to R36A.  A competitive inhibition assay (Fig. 
4)  indicated that  the four hybridoma antibodies  bound  different epitopes on 
R36A. Although some of the four antibodies competed with others in the assay, 
the relative inhibitory capacities of the four antibodies were different depending 
on which antibody's binding to R36A was being inhibited. The anti-PC antibody, 
22.1A4 (23), failed to inhibit the binding of the four non-PC-binding antipneu- 
mococcal hybrids  and  the  non-PC-binding  hybrids  also  failed  to  inhibit  the 
binding of anti-PC antibodies. 
Protection Against Infection with Type 3 S. pneumoniae.  To examine the ability 
of these antibodies to protect mice from pneumococcal infection, we intraperi- 390  ANTIPNEUMOCOCCAL  PROTEIN  ANTIBODIES 
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FIGURE  1.  Lack of reactivity of anti-R36A hybridoma antibodies with capsular and cell wall 
antigens. (A) Inhibition of antibody binding to R36A by PC chloride. Absorhance at OD 405 
nm (vertical axis) is a measure of the chromophore produced in the ELISA assay that detects 
antibodies bound to R36A. (B) Inhibition of antibody binding to R36A by C-polysaccharide 
as described in A. (¢) Inhibition  of antibody binding  to R36A by type 3 capsular polysaccharide. 
The  inhibition of the  anti-PC antibody with  type  3  polysaccharide is  likely the  result of 
contamination of type 3 polysaccharide with C-polysaccharide. McDANIEL  ET  AL.  391 
TABLE  I 
Binding Properties of Anti-R36A Hybridomas 
Hybridoma  Isotype  Reactivity 
with PC  R36A treated with: 
PDs0*  Percent bound to:  (#g/mouse) 
R36A  WU2  D39 
Pepsin  Trypsin 
Xi64  lgM  -  54  1  0.8  4.5  >200 
Xi126  IgG~b  --  16  4  0.5  2.6  112 
Xi69  IgM  -  10  -3  0.3  >700  >200 
HPR36A  IgM  -  20  -5  0.5  >700  ND* 
22.1A4  IgM  +  60  70  74  11.5  >200 
159.4D5  IgM~  +  ND  ND  ND  3.8  40 
* PDs0 doses were calculated at 10 d postinfection with I00 type 3 strain WU2 or type 2 strain D- 
39. 
* Not done. 
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FIGURE  2.  Inhibitors  in  the  crude  lysate  of R36A  that  block  the  binding of Xi126  and 
59.6C5 to heat-killed R36A. (A) Susceptibility of the inhibitor of Xi126 binding to trypsin. (B) 
Resistance of the inhibitor of 59.6C5 binding to trypsin. 
toneally  injected  various  concentrations  of antibody  1  h  before  intravenous 
challenge  with about five times the  LDs0 of type  3, strain WU2  pneumococci. 
All six mice injected with 20 #g of Xi64 and all six injected with 26 #g of Xi126 
were alive  10 d  after infection (Fig.  5).  In contrast, at  3  d  all six mice treated 
with 70 #g of Xi69  were dead and at 2  d  all unprotected mice were dead.  By 
combining the data in Fig. 5 with those of subsequent experiments, the doses of 
antibody  ÷equired  to  protect  50%  of  mice  from  fatal  infection  (PDs0)  was 
determined (Table I).  Xi64 and Xi126 were found to be even more protective 
than  the  IgM  anti-PC  antibody,  22.1A4,  while  Xi69  and  HPR36A  failed  to 
protect mice even at doses as high as 700 ~g per injection. 
In another experiment  we demonstrated  that  the  LDs0 of WU2  in  CBA/N 
mice given  20 vg of Xi64 or Xi126 was  104 and  106, respectively, as compared 392  ANTIPNEUMOCOCCAL  PROTEIN  ANTIBODIES 
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FIGURE 3.  Expression of antigens on  the surface  of different S. pneumoniae serot~pes  as 
12~'t"  /  determined by the binding of  I-labeled hybridoma antibodies. Approximately 5 x  10  viable 
12ffi  pneumococci were incubated with 20,000 cpm of the indicated  I-labeled antipneumococcal 
hybridoma antibody for 30 min at 37°C. 
with an LDs0 of 101 in unprotected CBA/N mice. The protective effects of these 
antibodies were also apparent when non-xid Swiss mice were used; 20 #g of Xi64 
and Xi126 were each able to protect against at least  100 (10  LDs0) A66 type 3 
S. pneumoniae.  This type 3 strain  is even more virulent than WU2 (12). 
Hybridoma antibody Xi 126 was also protective against fatal infection with the 
type  2  strain  D39  (Table  I).  The  possibility that  some of the  antiprotein  hy- 
bridoma antibodies might be protective against  D39 was anticipated  since D39 
was the parent of the rough strain R36A, against which the hybridoma antibodies 
were prepared.  The higher  PDs0 of Xi126 against D39 as compared with WU2 
may be due to a greater virulence of D39 than WU2 in xid mice. This would be 
consistent  with  the  observations  that  anti-PC  antibody  22.1A4  failed  to  be 
protective against D39 infection even at doses of 200 #g/ml, and that >10 times 
as much  of the  IgG1  anti-PC  hybridoma,  antibody  159.4D5,  was required  to 
protect against D39 as compared with WU2. 
Like  anti-PC  antibodies  (12),  the  antiprotein  antibodies  are  apparently  not 
protective against all of the pneumococcai strains to which they bind, since 200 
#g of either Xi64 or Xi126 was not able to protect mice from the type 5 or type 
6A strains that were tested in the experiment shown in Fig. 3. 
Discussion 
We  have  demonstrated  that  two hybridoma  antibodies  that  appear  to  bind 
pneumococcal  surface  proteins  can  protect  mice  from  experimental  infection 
with S. pneumoniae  strains WU2, A66, and  D39. We were surprised by the fact 
that  even  antiprotein  antibodies  raised  against  an  unencapsulated  laboratory 
strain  of pneumococci that  had  not been passaged through  mice for 40  years, 
would be protective against any virulent pneumococci. 
The  fact  that  these antibodies  were  not  protective against  tWO of the  pneu- 
mococcal  strains  tested  may  relate  in  part  to  differences  in  virulence  of the McDANIEL  ET  AL.  393 
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FIGURE  4.  Competition  for  R36A  surface  binding  sites  by  hybridoma  antibodies.  The 
indicated  concentrations  of  unlabeled  antibody  were  tested  for  their  ability  to  inhibit  the 
binding of a  standardized amount of labeled  antibody to the surface of  107 heat-killed  R36A 
during incubation  at 37°C  for  30 rain. 
different pneumococcal  strains for mice.  Alternatively,  the lack of the ability of 
these  antiprotein  antibodies  to  protect  against  all  strains  may  be  due  to  an 
inability  of the antibodies  to adequately  bind the proteins on those strains.  We 
are  attempting  to  test  this  possibility  by  raising  antiprotein  antibodies  to  the 
pneumococcal strains our present antibodies fail to protect against. 
All  four  of  our  hybridoma  antibodies  to  pneumococcal  surface  proteins, 
including  the  two antibodies  that  protect  against  pneumococcal  infection,  ap- 
peared  to  detect  closely  associated  epitopes  since  some  of them  were  able  to 
cross-inhibit the binding of the others. The relative ability of the four antibodies 394  ANTIPNEUMOCOCCAL  PROTEIN  ANTIBODIES 
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FIGURE 5.  Survival curve of CBA/N (x/d) male mice protected from type 3 S. pneumoniae 
with antipneumococcal protein hybridoma antibodies. Mice were protected by intraperitoneal 
injection of the indicated dose of antibody 1 h before intravenous challenge. 
to inhibit the binding of each other to R36A differed markedly, indicating that 
their  different  inhibitory  capacities  were  not  simply  the  result  of different 
affinities for the same determinant. It seems that the inhibition may be due to a 
complex pattern of steric hinderance. The conclusion that the antibodies have 
different specificities was further supported by their showing different patterns 
of reactivity with a panel of pneumococcal isolates. 
An eventual understanding of the nature of the antigen(s) recognized and the 
protective mechanisms involved could lead to the development of a pneumococ- 
cal vaccine containing protein antigens.  Such a  vaccine would be particularly 
important for the immunization of infants (a high risk group for pneumococcal 
infections) who fail to make adequate protective responses to the pneumococcal 
capsular polysaccharides that constitute the current vaccines (28-30). Although 
vaccines containing the capsular antigens are highly effective immunogens in 
adults (1), they fail to elicit adequate protective responses in very young children 
(28), probably because children make extremely low anticarbohydrate responses 
in general until they are at least 1 to 2 yr old (29-32). Since infants are generally 
responsive to protein antigens (33), an effective protein based vaccine would be 
more appropriate. 
The failure to detect protective antibodies to noncapsular antigens in  most 
previous studies might be partly because of the higher protection afforded by 
anticapsular antibodies (1-3) and partly because, when presented with the whole 
pneumococcus, containing many other antigenic structures, the protein antigens 
might not have been very immunogenic. This latter interpretation is consistent 
with our observation that a higher frequency of the anti-R36A hybridomas were 
directed against non-PC determinants when we immunized the xid mouse, which 
has great difficulty producing antibodies to carbohydrates, than when we used 
BALB/c mice. In this case the mechanism resulting in poor antibody responses 
to proteins on whole pneumococci may relate in part to the fact that the dominant 
antibody responses to a  complex antigen tend to inhibit primary responses by 
other B cell clones (25, 34-37). Of particular interest is the fact that when rabbits 
are immunized with heat-killed streptococci, as much as 95% of the antibody can McDANIEL  ET  AL.  395 
be directed against the group-specific polysaccharide, leaving 5% directed against 
other internal and external molecules on the bacterium (25, 38). 
Another possibility is that the capsule may block the antigenicity of cell wall 
antigens by simply covering them up. We recently observed that when xid mice 
are immunized with smooth rather than rough pneumococci, very few hybrido- 
mas producing antibody to either surface proteins or PC  were obtained (Mc- 
Daniel, Scott and Briles, unpublished results). 
Regardless of why the protective potential of these antibodies was not observed 
in  previous studies,  we hope that a  vaccine containing cell wall proteins,  free 
from other pneumococcal antigens will  elicit protection against pneumococci. 
Recently, a  similar  strategy  has  been  proposed  for  other  pathogens  such  as 
Haemophilus influenzae (39), where infants also fail to respond to the polysaccha- 
ride capsular antigens (32). 
Summary 
Monoclonal antibodies were raised against surface determinants of Streptococcus 
pneumoniae  by hyperimmunizing X-linked immunodeficient (xid)  CBA/N  mice 
with the heat-killed rough strain R36A.  17 hybridomas produced antibody that 
bound  intact  R36A  and  did  not  cross-react with phosphocholine, an  antigen 
common in the cell wall of all S. pneumoniae. The antibody produced by at least 
two of these hybridomas, Xi64  (IgM) and Xi126  (IgG2b),  could protect mice 
from a  lethal intravenous challenge of type 3  S.  pneumoniae  strains WU2 and 
A66 and of the type 2 strain D39. The minimum amount of antibody required 
to protect xid  mice from  100  WU2  was  4.5  #g/mouse for Xi64  and  2.6  #g/ 
mouse for Xi126.  Free phosphocholine, C-polysaccharide, and type 3 capsular 
polysaccharide all failed to inhibit the binding of Xi64 or Xi 126 to R36A. These 
antibodies appeared to bind surface polypeptides, since treatment of R36A with 
either pepsin or trypsin, or of R36A lysate with trypsin, effectively eliminated 
the ability of Xi64 and Xi 126  to bind antigens in  these preparations. Binding 
studies indicated that  these two antibodies recognized different epitopes that 
were expressed on several but not all serotypes of pneumococci. 
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